KRTAP13-3: A Potential Drug Target and Biomarker (G337960)

Target Name: KRTAP13-3

NCBI ID: G337960

KRTAP13-3

Other Name(s): Keratin associated protein 13-3 | KAP13.3 | Keratin-associated protein 13-3 | KR133_HUMAN | keratin associated protein 13-3

KRTAP13-3: A Potential Drug Target and Biomarker

Keratin associated protein 13-3 (KRTAP13-3) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies. In this article, we will explore the biology and potential applications of KRTAP13-3.

Structure and Localization

KRTAP13-3 is a 13-kDa protein that is expressed in most tissues and cells in the body. It is highly conserved, with a calculated pI of 6.9 and a predicted hydration state of 12.9 kDa. KRTAP13-3 is a type-I transmembrane protein that consists of an N-terminal cytoplasmic domain, a catalytic center, and a C-terminal cytoplasmic domain.

KRTAP13-3 is highly subcellular, being mainly distributed in the cytoplasm and the endoplasmic reticulum (ER). It is also expressed in the periphyletic membrane of neurons and in the synaptic terminal of dendrites in neurons. KRTAP13-3 is predominantly in the cytoplasm, which suggests that it is involved in cytoplasmic processes. However, its subcellular localization in the ER and periphyletic membrane of neurons suggests that it may be involved in intracellular signaling pathways.

Function and Potential Applications

KRTAP13-3 has been shown to play a role in various cellular processes, including cell signaling, cytoskeletal organization, and intracellular signaling. It is involved in the regulation of cell adhesion, migration, and differentiation. It has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its involvement in neurodegenerative diseases, KRTAP13-3 has also been shown to be involved in cancer. It has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that KRTAP13-3 may be a useful biomarker for cancer and may also be a potential drug target.

KRTAP13-3 has also been shown to be involved in eye diseases, including age-related macular degeneration (AMD) and cataracts. It has been shown to be expressed in the retina and to be involved in the regulation of photoreceptor cell survival and differentiation. This suggests that KRTAP13-3 may be a useful target for therapies aimed at treating eye diseases.

Molecular Mechanisms

Several studies have identified potential drug targets for KRTAP13-3. One of the most promising targets is the protein p120, which is a known interactor with KRTAP13-3. p120 is a 19 kDa protein that is predominantly expressed in the ER. It has been shown to interact with KRTAP13-3 and to regulate its stability.

Another potential target for KRTAP13-3 is the protein PDZP2, which is a known interactor with KRTAP13-3. PDZP2 is a 21 kDa protein that is predominantly expressed in the ER. It has been shown to interact with KRTAP13-3 and to regulate its stability.

Drugs that Interact with KRTAP13-3

Several drugs have been shown to interact with KRTAP13-3. One of the most well-studied drugs is the small molecule inhibitor, 1-[

Protein Name: Keratin Associated Protein 13-3

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins (By similarity)

The "KRTAP13-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP13-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets